Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis

Amit Kulkarni(University of Minnesota), Narjust Florez(Dana-Farber Cancer Institute), Brandon Hayes‐Lattin(Oregon Health & Science University), Daniel Flora(St. Elizabeth Healthcare), Wylie Hosmer(Hartford Hospital), Blanche H. Mavromatis(Western Maryland Health System), Nathaniel Bouganim(McGill University Health Centre), Grace Wilson(University of Minnesota), Gerald Batist(Jewish General Hospital), Ziad Bakouny(Dana-Farber Cancer Institute), Dani Ran Castillo(Loma Linda University), Chinmay Jani(Mount Auburn Hospital), Joy Awosika(University of Cincinnati), Lisa B. Weissmann(Mount Auburn Hospital), Jeremy L. Warner(Brown University), Diana Vilar‐Compte(Instituto Nacional de Cancerología), Clara Hwang(Henry Ford Health System), Vidhyalakshmi Ramesh(University of Minnesota), Benjamin French(Vanderbilt University Medical Center), Rana R. McKay(University of California San Diego), Sanjay Mishra(Vanderbilt University Medical Center), Elizabeth A. Griffiths(Roswell Park Comprehensive Cancer Center), Solange Peters(University Hospital of Lausanne), Gilberto Lopes(University of Miami), Babar Bashir(Thomas Jefferson University), Stephanie Berg(Loyola University Medical Center), Matthew Puc(Virtua Health), Jonathan W. Riess(University of California Davis Medical Center), Cassandra Hennessy(Vanderbilt University Medical Center), Hina Khan, Anup Kasi(University of Kansas Medical Center)
Clinical Lung Cancer
April 10, 2024
10.1016/j.cllc.2024.04.003
Cited by 3

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k